All of these observations suggest that beyond its classical roles in immunity, HLA-F might function as an “oncogenic driver” in the progression of GBM by regulating HK2-dependent glycolysis, at least partially, although we cannot rule out the roles of HLA-F in allowing cancer cells to escape immune system surveillance in vivo. The gene discussed is HK2; the disease is glioblastoma.